<?xml version="1.0" encoding="UTF-8"?>
<p>Similarly, on 1 May 2020, Mercuro 
 <italic>et al.</italic> in Boston, Massachusetts, investigated the risk of QT prolongation with the use of HCQ with or without azithromycin used in combination in COVID-19 confirmed-patients.
 <sup>
  <xref rid="bibr46-2049936120947517" ref-type="bibr">46</xref>
 </sup> They observed that patients receiving HCQ as a treatment for COVID-19 pneumonia were at significant risk for QT prolongation and that parallel treatment with azithromycin further elevated the risk. They emphasised extreme caution and careful monitoring of the patients with a careful weighing of both risk and benefits before initiation of the treatment with HCQ/azithromycin.
</p>
